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Abstract
Publication of accurate and detailed descriptions of methods in research articles involving
animals is essential for health scientists to accurately interpret published data, evaluate
results and replicate findings. Inadequate reporting of key aspects of experimental design
may reduce the impact of studies and could act as a barrier to translation of research find-
ings. Reporting of animal use must be as comprehensive as possible in order to take advan-
tage of every study and every animal used. Animal models are essential to understanding
and assessing new chemotherapy candidates for Chagas disease pathology, a widespread
parasitic disease with few treatment options currently available. A systematic review was
carried out to compare ARRIVE guidelines recommendations with information provided in
publications of preclinical studies for new anti-Trypanosoma cruzi compounds. A total of 83
publications were reviewed. Before ARRIVE guidelines, 69% of publications failed to report
any macroenvironment information, compared to 57% after ARRIVE publication. Similar
proportions were observed when evaluating reporting of microenvironmental information
(56% vs. 61%). Also, before ARRIVE guidelines publication, only 13% of papers described
animal gender, only 18% specified microbiological status and 13% reported randomized
treatment assignment, among other essential information missing or incomplete. Unfortu-
nately, publication of ARRIVE guidelines did not seem to enhance reporting quality, com-
pared to papers appeared before ARRIVE publication. Our results suggest that there is a
strong need for the scientific community to improve animal use description, animal models
employed, transparent reporting and experiment design to facilitate its transfer and applica-
tion to the affected human population. Full compliance with ARRIVE guidelines, or similar
animal research reporting guidelines, would be an excellent start in this direction.
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Author Summary
There is a growing concern about animal use for scientific purposes. In order to maximize
impact of results obtained and avoid unnecessary experiment repetition, certain strategies
have been implemented such as publication of guidelines to encourage detailed reporting of
animal studies. We contrasted information reported in publications assessing new com-
pounds for Chagas disease in animal models with the suggestions contained in the ARRIVE
guidelines. A significant lack of compliance with the guidelines was observed even years
after ARRIVE publication, including lack of minimally expected information. These results
illustrate the importance of promoting inclusion of detailed information on animal use, in
Chagas disease research in particular, but also in all research reporting in general.
Introduction
Chagas disease (also known as American Trypanosomiasis) is a widespread condition, caused
by the hemoprotozoa parasite Trypanosoma cruzi, affecting approximately 8 million people
worldwide[1]. Formerly considered an endemic illness in South America, it recently became
recognized as a global public health concern due to migratory movements [2].
Available drugs for Chagas disease, Nifurtimox (NFX) and Benznidazole (BZ), were devel-
oped more than 30 years ago. Although their efficacy in the acute phase of the infection is well
documented, clinical outcomes in chronic stages are more variables [2], and occurrence of
adverse events is common, especially in adults. Therefore, there is a considerable need for new
compounds to improve Chagas disease chemotherapy [3].
Animals models have commonly been employed to study mechanisms involved in patho-
genesis, immunological response, and to estimate efficacy of new chemotherapies and vaccines
for Chagas disease, among others [4].
Variability of animal models for Chagas disease, and the heterogeneity in readout methods
used to define drug response (e.g. parasitemia, PCR in blood, PCR in blood and in tissues) have
led to highly variable results when evaluating new drug candidates. This wide gap between results
in preclinical research and high failure rate in clinical trials may be explained, in part, by the
scarce information contained in most experiments that employ laboratory animals, in which cru-
cial information related to species, strains, genetic background, microbiological status, husbandry
conditions and procedures are not properly described or even missed in some occasions.
Inaccurate description of materials and methods and failure to report results appropriately
has significant scientific, ethical and economic implications both for the research community
and the public opinion. Furthermore, detailed reporting of animal use in scientific papers has a
direct connection with the “3Rs’ Principles” of humane use of animals in scientific research
(i.e. Replacement, Reduction and Refinement) since a complete and systematic description of
what was done and what was found in the experiments may avoid unnecessary repetition [5],
facilitate systematic revisions before new essays involving animals are carried out,[6] and sim-
plify comparisons and data integration from different studies [7].
The Animals in Research: Reporting in vivo Experiments (ARRIVE) Guidelines were pub-
lished in June 2010. The main objectives of the ARRIVE guidelines are to improve the quality
of animal use reporting in scientific publications to maximize the availability and utility of
information gained from every animal in every experiment, preventing unnecessary animal
use, and to allow an accurate critical review of animal experiments, making results easier to
compare among different research groups to validate and contextualize results to promote
translational research to patients’ benefit [8].
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The ARRIVE Guidelines consist in a checklist describing the minimum information that all
scientific publications using animals should include, such as number and specific characteris-
tics of animals employed; details of housing, husbandry and procedures; experimental design,
statistical and analytical methods [8].
The main objective of this systematic review was to evaluate the degree of compliance with
ARRIVE guidelines of scientific publications assessing efficacy of new chemotherapy for T.
cruzi in animal models. The secondary objective was to compare these results to information
presented in similar papers published before the ARRIVE guidelines were made available.
Materials and Methods
Publication search strategy
A systematic search was carried out in PubMed database (National Library of Medicine, USA)
to identify potentially relevant scientific papers reporting original research on efficacy of new
drugs for Chagas disease using animal models.
A modified filter suggested by Hooijmans et al. was used to find all studies in PubMed
reporting animal experiments to evaluate drugs for Chagas disease [6]. Modifications consisted
in restricting the search only to studies including mammals. The following MeSH (Medical
Subject Headings) terms and connectors were used: Chagas disease OR trypanosoma cruzi
AND chagas disease/drug therapy AND animal model.
In order to compare information present in papers published before and after ARRIVE
guidelines became widely available the search was performed between 2008/06/30 to 2011/06/
30 (i.e before ARRIVE publication) and between 2011/07/01 until 2014/06/30 (i.e. after publi-
cation), respectively. The dates for the search period after ARRIVE guidelines publication were
set one year after ARRIVE guidelines actual publication to allow scientific community
(researchers, reviewers, editors and journals) to adopt them (Fig 1).
Abstracts were reviewed manually and the ones which did not meet inclusion criteria were
discarded. Supplementary Material (S2 Fig) illustrates search filters used.
Evaluation of publications
Relevant publications fulfilling inclusion criteria were randomly assigned to independent
reviewers, ensuring that revision was done blindly until the final compilation of results.
The ARRIVE guidelines were used to analyze the papers focusing on the “Material and
methods” section to evaluate the degree of compliance of the publicatons with the guidelines.
Issues addressing animal model information, husbandry conditions, ethics and strategies
implemented to follow 3R’s Principles were compared to the checklist.
Refined approaches established to avoid or minimize pain or stress such as days acclimation
before the study starts, refined oral administration with minimum volume and / or oral gavage
replacement with a pipette tip instead of oral gavage were considered. Also, anticipated end
points determined by parasitaemia peak or severe adverse drug effects were included as refine-
ment strategies.
Statistics
Reported information rates before and after the ARRIVE guidelines publication were com-
pared using Chi-square test. P values< 0.05 were considered statistically significant in all
cases. Statistical calculations were performed in R version 3.1 (The R Foundation for Statistical
Computing ISBN 3-900051-07-0).
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Results
A total of 39 articles (out of 176 identified by the search terms) fulfilled inclusion criteria in the
period before ARRIVE guidelines publication, and 44 (out of 129 identified) fulfilled inclusion
criteria in the period after the guidelines were published.
Supplemental material 1 (S1 Fig) summarizes number of papers included in this review, by
publication year. S1 Text contains the complete list of supporting references.
Information about animals used
Before ARRIVE guidelines publication, animal models for Chagas disease were more diverse.
Even though Mouse (Mus musculus) was the most popular species used (34 / 39), some papers
reported studies on Rat (Rattus norvegicus) and Dog (Canis lupus familiaris). When Mouse
Fig 1. Flow diagram summarizing search strategy.
doi:10.1371/journal.pntd.0004194.g001
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models were used, inbred strains were used slightly more than outbred stocks (18 / 32 vs. 14 /
32).
After ARRIVE guidelines were published, the only animal species reportedly employed to
assess in vivo efficacy of new compounds for Chagas disease was the Mouse. Half of the publi-
cations used inbred strains (22 / 44). There was a considerable predominance of BALB/c strains
and Swiss mice stocks in the inbred and outbred experiments, respectively. Table 1 shows in
detail all animal models and strains employed.
Before ARRIVE guidelines appeared, animal gender was not reported in 13% of papers (5 /
39) while females were more used than males (20 / 39 vs. 12 / 39) and both sexes were used in
two papers. After ARRIVE guidelines, male and female animals were employed almost in the
same proportion (16 / 44 vs. 20 / 44) and only one paper used both sexes in the same experi-
ment. Within this period, sex information was not reported in 16% of papers (7 / 44) (Table 2).
Basic details about animal age, weight and microbiological status and source (Tables 3 and
4) were not provided in almost half of the reviewed publications, both pre- or post publication
of ARRIVE guidelines.
Macroenvironmental information such as room temperature was detailed in nearly the
same proportion before and after ARRIVE guidelines publication (10 / 39 vs. 16 / 44), but
Table 1. Detail of animal models.
Before-ARRIVE After-ARRIVE
Animal species Ratio % Ratio %
Mice 34 / 39 87 44 / 44 100
Inbred 18 / 32 56 22 / 44 50
BALB/c 12 / 18 67 18 / 22 82
C3H 5 / 18 28 2 / 22 9
C57BL/6 (Ly5.2+) 1 / 18 6 1 / 22 5
NIH - - 1 / 22 5
Outbred 14 / 32 44 22 / 44 50
Swiss 12 / 14 86 20 / 22 91
CD-1 1 / 14 7 2 / 22 9
Swiss and CD-1 1 / 14 7 - -
In and outbred 2 / 32 6 - -
BALB/c and Swiss 1 / 2 50
C3H and Swiss 1 / 2 50
Rat 4 / 39 10 - -
Wistar 4 / 4 100
Dog 1 / 39 3 - -
doi:10.1371/journal.pntd.0004194.t001
Table 2. Details of animal gender used in papers.
Before-ARRIVE After-ARRIVE
Sex Ratio % Ratio % p-value
Male 12 / 39 31 16 / 44 36 0.81
Female 20 / 39 51 20 / 44 45 0.81
Male and female 2 / 39 5 1 / 44 2 -
Not speciﬁed 5 / 39 13 7 / 44 16 -
doi:10.1371/journal.pntd.0004194.t002
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reporting of light/dark cycle increased from 23% (9 / 39) to 43% (19 / 44) respectively, although
not statistically significant.
In addition, more than half of the analyzed studies in both periods failed to mention any
macroenvironmental parameters or included ambiguous information. However, the percentage
decreased from 69% (27 / 39) to 57% (25 / 44) after publication of ARRIVE guidelines
(Table 5), but this change was not enough to reach statistical significance.
Concerning microenvironmental conditions, access to food and water (mostly ad libitum),
was reported in same proportion (17 / 39 vs. 21 / 44) in papers published before or after
ARRIVE guidelines appeared. Similarly to macroenvironmental details, more than half of the
analyzed studies (22 / 39 and 27 / 44) failed to provide any microenvironmental information
for both periods of time (Table 6).
Information about ethical statement and 3R’s Principles
Before ARRIVE guidelines became widely available, approximately 51% of papers on animal
models evaluating drugs for Chagas disease included a statement about compliance with local
or international guidelines for experimentation with animals. This percentage increased to
66% (p = 0.26) after ARRIVE guidelines were published.
Reporting of protocol revision and approval by an Institutional Animal Care and Use Com-
mittee (IACUC) increased from 26% (10 / 39) to 41% (18 / 44) after ARRIVE guidelines publi-
cation (p = 0.22) (Table 7).
The number of papers that mentioned refined strategies and procedures increased from
15% (6 / 39) to 23% (10 / 44) after ARRIVE guidelines publication. Ten publications mentioned
proceedings which would require anesthesia/analgesia (such as terminal bleeding. biolumines-
cence imaging techniques); seven of these reports (70%) described the procedures only as
“under anesthesia” or “with anesthetized mouse” without further details, while two of them
specifically reported isofluorane use.
The vast majority of the reviewed papers failed to mention euthanasia methods. Some
papers published before ARRIVE guidelines applied methods not accepted nowadays; only
three reported carbon dioxide use, all of them published after the ARRIVE guidelines
(Table 8).
Table 3. Details of animal models for Chagas disease.
Before-ARRIVE After-ARRIVE
Details given Ratio % Ratio % p-value
Age range 25 / 39 64 26 a/ 44 59 0.81
Weight range 26 / 39 67 20 / 44 45 0.85
Speciﬁed source 16 / 39 41 21 / 44 48 0.69
doi:10.1371/journal.pntd.0004194.t003
Table 4. Microbiological status from experimental animals.
Before-ARRIVE After-ARRIVE
Microbiological status Ratio % Ratio % p-value
Speciﬁc Pathogen Free (SPF) 4 / 39 10 3 / 44 7 0.86
Conventional 3 / 39 8 4 / 44 9 0.99
Not speciﬁed 32 / 39 82 37 / 44 84 0.99
doi:10.1371/journal.pntd.0004194.t004
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Reported experimental design and sample size calculation data
The ARRIVE guidelines checklist includes statements about reporting of sample size calcula-
tions and statistical methods used. More than 60% (27 / 39 and 27 / 44) of the reviewed papers,
all published after ARRIVE guidelines, reported the statistical tests used to analyze results, but
only 11% (5 / 44) gave information about data distribution,
Regarding experimental design, a similar proportion of papers from both periods (5 / 39
and 7 / 44) declared treatment randomization or any effort to minimize subjective bias (e.g.
randomized block design). None of the publications in any studied period substantiated the
sample size employed (Table 9).
Animal models for Chagas disease
Tables 10–16 show different characteristics of reported animal models of T. cruzi infection.
To assess efficacy of new compounds, acute infection was the preferred phase to start treat-
ment, both before and after ARRIVE guidelines publication. In only 1 (3%) and nine papers
(20%), before and after ARRIVE respectively, drugs were tested in both acute and chronic stage
in separated essays. No rationale was provided for studying parasiticidal effects of drugs in
chronic animal models.
Most used T. cruzi strains were Y strain and Tulahuen, in 38 and 27% (before ARRIVE) and
15 and 18% papers (after ARRIVE), respectively. Furthermore, thirteen publications in total
reported assessing compound efficacy on more than one T. cruzi strain.
A wide range of inoculum sizes were reported, from less than 1,000 to more than 100,000
trypomastigotes per animal. Inoculation was intraperitoneal in the vast majority of papers (87
Table 5. Macroenvironmental details.
Before-ARRIVE After-ARRIVE
Macroenvironment details Ratio % Ratio % p-value
Temperature 10 / 39 26 16 / 44 36 0.42
Humidity 0 / 39 0 1 / 44 2 0.99
Light/Dark cycle 9 / 39 23 19 / 44 43 0.89
Not speciﬁed a 27 / 39 69 25 / 44 57 0.35
a Includes statements as "standard conditions", "controlled environment", "temperature-controlled room" and one which refers to a previous published
paper.
doi:10.1371/journal.pntd.0004194.t005
Table 6. Microenvironment details.
Before-ARRIVE After-ARRIVE
Microenvironment details Ratio % Ratio % p-value
Type of cage 4 / 39 10 0 / 44 0 0.09
Bedding material 1 / 39 3 1 / 44 2 0.99
# of cage companions 7 / 39 18 11a / 44 25 0.61
Access to food and water 17 / 39 44 21 / 44 48 0.88
Not speciﬁed b 22 / 39 56 27 / 44 61 0.81
a Includes 2 papers which declares individual cages for better management.
b Includes statements as "standard conditions" and one which refers to a previous published paper.
doi:10.1371/journal.pntd.0004194.t006
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and 95%, before and after ARRIVE respectively), whilst 3 to 5% of papers did not specify such
information.
Before ARRIVE guidelines publication, treatment was administered most commonly by
oral (13 / 39) or intraperitoneal routes (14 / 39). After ARRIVE treatment was reportedly
administered by the oral route in half of the reviewed papers, while eleven (25%) preferred the
intraperitoneal route. Treatment initiation, schemes and duration were reported with large
variations.
Discussion
Research involving animal studies is essential to many disciplines in the biomedical sciences.
Detailed descriptions in publications of experimental methods and results enable researchers
to interpret data, evaluate results accurately, replicate findings and move science forward [9].
The “Materials and methods” section of research papers is intended to provide basic infor-
mation about how the research was performed. Comprehensive reporting is essential to cor-
rectly understand how investigations were undertaken, to properly interpret findings [10] and
to compare and integrate results obtained from previous experiments.
Consistent reporting of animal use is directly related to scientific quality. Employed animals
should not be unnecessarily stressed and should be kept under appropriately controlled condi-
tions: poor animal welfare is likely to result in poor science [11]. Moreover, experiments
involving animals have also ethical requirements and are increasingly scrutinized by the public
opinion.
Table 7. Ethical statements in animal models for Chagas disease.
Before-
ARRIVE
After-ARRIVE
Ethical statements Ratio % Ratio % p-value
Refers to guidelines a 20 / 39 51 29 / 44 66 0.26
Protocol approbation without number of permission 11 / 39 28 15 / 44 34 0.73
Protocol approbation with number of permission 10 / 39 26 18 / 44 41 0.22
a National or international guidelines.
doi:10.1371/journal.pntd.0004194.t007
Table 8. Welfare-related assessments.
Before-ARRIVE After-ARRIVE
Welfare-related assessments Ratio % Ratio % p-value
Anesthesia, analgesia a 8 / 16 50 6 / 10 60 0.93
Reﬁnement strategies 6 b / 39 15 10 c / 44 23 0.57
Euthanasia method 6 d / 39 15 3 e / 44 7 0.37
a Applied for non-invasive procedures (electrocardiogram, bioluminescence imaging) or for terminal bleeding.
b Includes 3 days to acclimation before study star/ and statement to follow 3R's principle.
c Includes anticipated end points in parasitaemia peak or with severe adverse effects, reﬁned oral administration or oral volume up to 50 μL/animal or 7 to
10 days to acclimation before study starts.
d Methods: tribromoethanol followed by decapitation; dyethyl-ether followed by cervical dislocation; thiopental overdose; CO2 inhalation.
e CO2 inhalation in all cases.
doi:10.1371/journal.pntd.0004194.t008
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Minimum information guidelines seek to promote transparency in experimental reporting,
enhance accessibility to data and support effective quality assessment, which increases the gen-
eral value of data, and therefore, of scientific evidence [7].
In this sense, some initiatives such as the Guidance for the Description of Animal Research
in Scientific Publications by the National Research Council (NRC), the Gold Standard Publica-
tion Checklist (GSPC) [12] and the Animals in Research: Reporting in vivo Experiments
(ARRIVE) [8], have been published with the aim to be adopted as a requirement for
publication.
For this review, ARRIVE guidelines were used as a benchmark to measure quality in animal
use reporting use because of its wide acceptance, and its useful checklist to easily identify key
information.
Chagas disease is one of the seventeen neglected disease prioritized by World Health Orga-
nization and a secure and effective treatment is urgently needed. Despite high throughput
screening systems and growing capacity to identify anti-T. cruzi compounds, both from phar-
maceutical companies’ libraries and the public domain, many lead compounds with promis-
sory results in animals models of infection have unfortunately failed in clinical trials [3,13].
To evaluate the quality of information reported in articles referred to new compounds for
Chagas disease, we contrasted descriptions of animal use and care with those descriptions sug-
gested by the ARRIVE Guidelines, using the guidelines checklist. In order to compare the qual-
ity of report before and after the ARRIVE guidelines publication, the date period for the search
was selected from 2008/06/30 to 2014/06/30, a year after ARRIVE guidelines first appearance
in print.
Table 9. Experimental design in animal models for Chagas disease.
Before-ARRIVE After-ARRIVE
Experimental design Ratio % Ratio % p-value
Treatment randomization or steps to minimize subjective bias 5 a / 39 13 7 / 44 16 0.93
Sample size calculation 0 / 39 0 0 / 44 0 0.99
Methods used to assess data distribution 0 / 39 0 5 b / 44 11 0.057
Statistical methods used for analysis 27 / 39 69 27 / 44 61 0.50
a Includes one randomized blocking design by cage (one replication for each treatment group in same cage).
b Includes one paper which refers to "homogeneous" or "heterogeneous" data.
doi:10.1371/journal.pntd.0004194.t009
Table 10. Experimental characteristics in animal models for Chagas disease.
Experimental infection model Before-ARRIVE After-ARRIVE
Phase disease under treatment Ratio % Ratio %
Acute phase 37 / 39 94 33 / 44 75
Sub acute phase a - - 1 / 44 2
Chronic phase 1 / 39 3 1 / 44 2
Acute and chronic phase b 1 / 39 3 9 c / 44 20
a Deﬁned as 40 dpi.
b Treatment at both phases in same paper.
c Includes 2 papers which do not treat in chronic phase, only antibody follow up.
doi:10.1371/journal.pntd.0004194.t010
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We observed that before publication of the ARRIVE guidelines, animal species used as mod-
els for experimental infection with T. cruzi seemed more diverse, even though mice were the
most commonly employed. After ARRIVE publication,Mus musculus was the only species
used to assess efficacy of new chemotherapies for Chagas disease in the papers published. This
election of animal model may be explained by the historical use of mice to evaluate new com-
pounds [14,15] and by the conclusions reached at the Experimental Models in Drug Screening
and Development for Chagas Disease workshop, held in Rio de Janeiro, Brazil in 2008, which
suggested the use of the Mouse model [16]. However, no justifications for the chosen animal
models were provided in any of the papers reviewed.
There is possibly no ideal animal model to test drugs for Chagas disease (i.e. an exclusively
Human disease), but some models may better mimic particular aspects of the disease [17].
Given that only animal species used after publication of ARRIVE guidelines, (i.e. the Mouse),
Table 11. T. cruzi strains employed in animal models for Chagas disease.
Before-ARRIVE After-ARRIVE
T. cruzi strain Ratio % Ratio %
Y 15 / 39 38 12 a / 44 27
Tulahuén 6 / 39 15 8 b / 44 18
H4 1 / 39 3 4 / 44 9
CL Brener c 2 / 39 5 - -
CA-I/72 2 / 39 5 - -
Maracay 3 / 39 8 - -
SN3 - - 5 / 44 11
Brazil - - 2 / 44 5
More than one strain in study 5 / 39 13 8 / 44 18
Other strain 4 / 39 13 5 / 44 11
a Includes transfected Y-luciferase.
b Includes Tulahuén 20A clone.
c Includes CL Brener-clone 5.
doi:10.1371/journal.pntd.0004194.t011
Table 12. Inoculum size for experimental animal models for Chagas disease.
Inoculum size a Before-ARRIVE After-ARRIVE
For acute phase model Ratio % Ratio %
<1.000 4 / 39 10 5 / 40 3
1.000–5.000 11 / 39 28 11 / 40 23
10.000–50.000 10 / 39 26 23 / 40 53
100.000 6 / 39 15 9 / 40 23
2000/kg 1 / 39 3 - -
For chronic phase model
<1.000 1 / 39 3 2 / 11 18
1.000–5.000 - - 3 / 11 27
10.000–50.000 - - 2 / 11 18
100.000 - - 4 /11 36
Different inoculum in same work 6 / 36 17 4 / 44 9
a trypomastigotes/animal
doi:10.1371/journal.pntd.0004194.t012
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may not resemble all Chagas disease stages and their complexity in the human host, other ani-
mal species with pathogenesis more similar to the Human (eg. Guinea pigs (Cavia porcellus))
[18] could be employed, depending on the aim of the research or whether encouraging results
are obtained in a murine model of infection.
Among mice, we observed that inbred and outbred strains were employed in same propor-
tion. Strain selection is a crucial decision due differences and variability in response.
Inbred strains are genetically defined and frequently stable, homogenous, and more often
lead to repeatable outcomes than ‘‘genetically undefined” outbred stocks. Experiments with
Mouse inbred strains may be more powerful with more accurate dose-response relationships
and fewer false negative results than those carried out using outbred stocks [19].
Outcomes in animal models of T. cruzi infection are dependent on many factors, including
animal species, strain, age, sex, T. cruzi strain, inoculum size and route of infection, among oth-
ers [20]. Since several variables contribute to establish an in vivomodel, reported information
must be as detailed as possible.
In the papers reviewed from the period after ARRIVE publication, information on animal
gender was not provided in seven publications (16%), a proportion similar to that observed
before ARRIVE guidelines publication (13%). In a similar previous survey, Kilkenny et al.
revealed that in 24 of 72 reviewed papers (33%) sex was not reported [21]. This observed lack
of detail in reporting undermines repeatability and robustness of studies, since some research
suggests that response to infection in male mice is different from females which are, apparently,
more resistant to T. cruzi infection [22,23]. Interestingly, a few of the reviewed papers used
both sexes, but did not analyze results with a factorial design missing the opportunity to test
for interactions between factors (sex) and drug response or disease progression [23–25].
Table 13. Inoculation route of T. cruzi in animal models for Chagas disease.
Before-ARRIVE After-ARRIVE
Inoculation route Ratio % Ratio %
Intraperitoneal 31 / 39 87 42 / 44 95
Intradermal 3 / 39 8 - -
Subcutaneous 1 / 39 3 - -
Not speciﬁed 1 / 39 3 2 / 44 5
doi:10.1371/journal.pntd.0004194.t013
Table 14. Treatment route in animal models for Chagas disease.
Before-ARRIVE After-ARRIVE
Treatment route Ratio % Ratio %
Oral 13 / 39 33 22 / 44 50
IP 14 / 39 36 11 / 44 25
Oral–Intraperitoneal 4 / 39 10 8 / 44 18
Oral ad-libitum a - - 2 / 44 5
Oral -Subcutaneous 2 / 39 5 - -
IV 4 / 39 10 1 / 44 2
SC 2 / 39 5 - -
Not speciﬁed - - - -
a in water/food.
doi:10.1371/journal.pntd.0004194.t014
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Table 15. Treatment initiation in animal models for Chagas disease.
Before-ARRIVE After-ARRIVE
Treatment initiation Ratio % Ratio a %
0 to 48 hs after infection 16 / 39 41 10 / 51 20
At parasitaemia onset 13 / 39 33 32 / 51 63
At subacute phase b - - 1 / 51 2
Chronic treatment c 1 / 39 3 4 / 51 8
Not speciﬁed 3 / 39 8 2 / 51 4
Various schemes 6 / 39 15 - -
Before infection d - - 2 / 51 4
a Over a total of 51 models employed.
b Deﬁned at 40 dpi.
c Deﬁned at 60, 75, 90 or 120 dpi.
d 14 days or 24 hours pre infection.
doi:10.1371/journal.pntd.0004194.t015
Table 16. Treatment length and schedule in animal models for Chagas disease.
Length of treatment Ratio % Ratio %
180 consecutive days - - 1 / 51 2
90 consecutive days 2 / 39 5 - -
60 consecutive days 1 / 39 3 2 / 51 4
35 consecutive days - - 2 / 51 4
30 consecutive days 4 / 39 10 4 / 51 8
28 consecutive days 1 / 39 3 2 / 51 4
21 consecutive days 3 / 39 8 - -
20 consecutive days 6 / 39 15 11 / 51 22
15 consecutive days 2 / 39 5 2 / 51 4
14 consecutive days 3 / 39 8 - -
13 consecutive days 1 / 39 3 1 / 51 2
10 consecutive days 1 / 39 3 - -
7 consecutive days - - 1 / 51 2
5 consecutive days 4 / 39 10 9 / 51 18
Ad libitum in water or chow - - 2 / 51 4
Different schedules 7 / 39 18 6 / 51 12
60 doses 1 a / 39 3 - -
10 doses 1 b / 39 3 - -
5 doses 1 c / 39 3 - -
2 doses - - 1 d / 51 2
1 dose at the peak - - 1 e / 51 2
1 dose at 3 dpi 1 / 39 3 - -
a 1 daily dose, 6 days/week, for a total of 60 doses.
b Consecutive doses or every other day.
c 3 consecutives doses every 24 hs, and 2 doses every 24 hs after 24 hs.
d At 5 and 8 dpi.
e At 19 or 24 dpi.
doi:10.1371/journal.pntd.0004194.t016
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Regrettably, other key information such as age and weight range at time of infection was
missing in more than the half of the publications both before and after the ARRIVE guidelines
publication. This omission prevents further testing of covariates, if necessary, as these variables
may modify the final outcome of certain models.
Animal source is not reported in more than 50% of papers, irrespective of period studied;
This, added to the lack of information on animal microbiological status, goes clearly in detri-
ment of quality standards of any preclinical studies. Besides, results can be distorted and mis-
understood by concurrent infections, as reported previously in a biological characterization of
a T. cruzi strain [26].
Macro and microenvironment are essential variables which influence animal well-being
and, accordingly, repeatability and reproducibility of the results. This information was incom-
plete or totally absent in more than half of the papers from both periods reviewed. ARRIVE
guidelines do not seem to have had an impact on reporting of these variables since there were
no significant differences between information provided in articles published before or after
ARRIVE release. For instance, exposure to wide extremes temperature may result in behav-
ioral, physiologic, and morphologic changes, which might negatively affect animal well-being
and research performance as well as outcomes of research protocols. [27]. The standard tem-
perature range for mice and other rodents is 23 ± 3°C to prevent triggering compensatory
thermoregulatory mechanisms that can affect animal health, and alter experimental results. A
good management program provides environment, housing, and care that minimizes varia-
tions that can affect research [28]. Unfortunately, more than half of the papers evaluated from
both periods did not report any information about macroenvironmental conditions. Similarly,
more than 50% of publications did not report any information relative to microenvironment
variables. These factors can potentially influence experimental results and are therefore scien-
tifically important so it is unclear why omission of these essential details is so prevalent.
Two papers admitted to housing animals in individual cages, “for better management”. This
can make workload easier for personnel, but when it comes to animal welfare, individual caging
can be more harmful since solitary confinement may increase alter immunological responses,
produces changes in body and organ weights and alterations in blood cell counts, among oth-
ers, potentially affecting drug response [28]. Adding to this, there is a growing concern in pub-
lic opinion about animal laboratory testing and a well-detail husbandry conditions may
contribute to proper understanding even to lay public. What is written in those reports, and
how it is written, may thus be crucial to the public perception of animal experiments [11].
Investigators conducting research with animal subjects have an ethical and legal responsibil-
ity to ensure they are treated humanely. Scientists are required to conduct their studies in com-
pliance with a framework of federal, state, local, and institutional rules and regulations [29].
It is widely accepted that applying 3R’s Principles to experiments using animals is in conso-
nance with good scientific practice [21]. Since there is no validated replacement method yet to
assess efficacy and safety compounds for Chagas disease treatment in humans, animals models
are expected to fill the gap between in vitro testing and clinical trials. Therefore, strategies to
refine procedures and reduce pain and distress are desired.
Typically, parasitaemia values and mortality were the principal outcomes used to assess try-
panocidal activity in the papers reviewed. Times have changed and it is currently necessary to
establish and validate anticipated endpoints (i.e. endpoints that can predict death and can be
used to avoid unnecessary suffering or distress in the experimental animals), which carries ben-
efit for both researchers (e.g. they do not lose samples for histopathology, sera, etc) and animals
(e.g. avoiding stressing death as result of sickness behavior and septic shock) [30].
At any rate, only 14% (5 / 36) and 23% (10 / 44) of papers (before and after ARRIVE guide-
lines publications, respectively) applied any refinement strategy, including anticipated
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endpoints at parasitaemia peak or with severe adverse effects, with a clear, but unjustifiably
modest, increment in papers appeared after ARRIVE guidelines arise.
A comprehensive analysis of experimental design and statistical methods is beyond the
scope of this review, but many topics recommended in the ARRIVE guidelines are missing or
incomplete from analyzed publications,. Treatment randomization, an essential step to avoid
experimental bias, was declared only in 16% (7 / 44) publications.
Sample size was not justified in any of the papers, suggesting that there was no previous
sample size calculation, and that animal numbers were more a matter of habit than a statistical
decision. One may argue that is difficult to predict parasitaemia levels in this models, and that
dispersion is very large (due in part to direct counting methods in Neubauer chamber or
between glass side and cover slip) which would make determining accurate sample size diffi-
cult. Nevertheless, strategies exists to justify number of animals employed such as conducting
previous pilot studies, or applying Mead’s resource equation, suitable in cases where there is no
information about standard deviation and/or it is difficult to specify an effect size [31,32].
These results agree with a previous quality of reporting survey which observed that only 5 in
72 (7%) of studies using mice informed sample size calculations or treatment randomization
[21].
Statistical methods were declared and detailed in nearly 2/3 of publications, but since there
was no information about data distribution, a proper analysis of the correct application of
these methods cannot be established.
As result from a workshop held in 2008 [16], guiding principles for drug testing in animal
models of Chagas disease were put forward, in which certain experimental variables were
agreed upon in order to perform similar research in different groups, allowing to screen candi-
date compounds and discard or move forward rapidly compounds to further testing.
Although original standardized protocols could be modified and updated, the initiative was
very promissory but only partially accepted by the Chagas scientific community given the vari-
ety of existing animal models using different mice and parasite strains, inoculums sizes, treat-
ment schedules and others differing factors. Unfortunately, it seems that standardization of
animal models is no easy in the field, possibly due to difficulties in accessing animal and/or par-
asite strains from different those already in use by each group. The fact that parasite strains in
particular, are not easy (or cheap) to transfer across country borders, among other issues,
should be kept in mind when judging this difficulties.
Finally, regarding suggestions put forward by Romanha et al., only 50% of the publications
described the use of oral treatment (as suggested), and 63% of the studies started treatment
with patent parasitaemia. Also, less than one-fourth (22%) of studies performed a treatment
for at least 20 consecutive days, indicating an incomplete and partial adherence to the sug-
gested guidelines for in vivo drug screening for Chagas disease [16].
Our results illustrate a general lack of compliance with ARRIVE guidelines in research
involving animals for testing of efficacy of new compounds for Chagas disease treatment.
Other fields in preclinical research are not exempt from these problems, according to conclu-
sions obtained in a survey conducted in experimental autoimmune encephalomyelitis and mul-
tiple sclerosis two years before ARRIVE publication [33]. Unfortunately, we observed that
publication of clear guidelines such as ARRIVE was not sufficient to improve reporting of ani-
mal studies, at least in the field of Chagas disease drug research.
In conclusion, a systematic review has been carried out to measure adherence degree to
ARRIVE guidelines in animal models for new chemotherapy for Chagas disease treatment.
There is vast key information missed or incomplete which difficult proper evaluation and com-
prehension of obtained results. Ensuring animal well-being and responsible use while meeting
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scientific aims must be emphasize to allow translational research to contribute to resolve
affected population problems.
This review does not want to cast doubt the results obtained in the evaluated papers, and is
not its matter examine their scientific merits. On the contrary, it attempts to warn about the
weak reporting quality in search of new chemotherapy compounds for Chagas disease and has
a teaching intention to encourage scientific community to adopt ARRIVE guidelines to cor-
rectly report their preclinical trial results and to unify animal models in order to maximize
obtained information and to be more transparent inside and outside the academic field.
We did not observe an improvement in publication quality after ARRIVE guidelines publi-
cation, compared to the previous period. There is a clear need to improve design and reporting
of animal research studies in Chagas disease. Full compliance with ARRIVE guidelines would
be a welcome starting point.
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